{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:57:51Z","timestamp":1790258271018,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008976","name":"Sanofi-Aventis Korea Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.eururo.2019.08.006","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:46:03Z","timestamp":1566521163000},"page":"719-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"title":["Abiraterone in \u201cHigh-\u201d and \u201cLow-risk\u201d Metastatic Hormone-sensitive Prostate Cancer"],"prefix":"10.1016","volume":"76","author":[{"given":"Alex P.","family":"Hoyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-8204","authenticated-orcid":false,"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-7983","authenticated-orcid":false,"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3954-2806","authenticated-orcid":false,"given":"David P.","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Brawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Gilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Ingleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-6555","authenticated-orcid":false,"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Millman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair W.S.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Douis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":false,"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.08.006_bib0005","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.08.006_bib0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.08.006_bib0015","author":"EMA"},{"key":"10.1016\/j.eururo.2019.08.006_bib0020","series-title":"FDAC for DER. Zytiga (abiraterone acetate) plus prednisone approved for treatment of patients with metastatic high-risk castrate sensitive metastatic prostate cancer","author":"FDA","year":"2018"},{"key":"10.1016\/j.eururo.2019.08.006_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1745-6215-12-81","article-title":"Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit","volume":"12","author":"Royston","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2019.08.006_bib0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice\u2014stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2019.08.006_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1745-6215-10-39","article-title":"Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial","volume":"10","author":"Sydes","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2019.08.006_bib0040","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djn267","article-title":"Speeding up the evaluation of new agents in cancer","volume":"100","author":"Parmar","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.08.006_bib0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.clon.2008.07.002","article-title":"STAMPEDE: systemic therapy for advancing or metastatic prostate Cancer\u2014a multi-arm multi-stage randomised controlled trial","volume":"20","author":"James","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2019.08.006_bib0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.08.006_bib0055","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2019.08.006_bib0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrurol.2016.175","article-title":"Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations","volume":"14","author":"Tosoian","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.08.006_bib0065","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2006.10.045","article-title":"The natural history of noncastrate metastatic prostate cancer after radical prostatectomy","volume":"51","author":"Yossepowitch","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.08.006_bib0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","article-title":"Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning","volume":"169","author":"Glass","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.08.006_bib0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","article-title":"Contemporary role of androgen deprivation therapy for prostate cancer","volume":"61","author":"Pagliarulo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.08.006_bib0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.08.006_bib0085","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.08.006_bib0090","series-title":"Variation in prevalence of high and low volume metastatic prostate cancer from the original comparison in the STAMPEDE trial","author":"Hoyle","year":"2018"},{"key":"10.1016\/j.eururo.2019.08.006_bib0095","first-page":"65","article-title":"The importance of non\u2010regional lymph nodes in assigning risk in primary metastatic prostate cancer","author":"Ali","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.08.006_bib0100","series-title":"Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastases and no visceral metastases. Exploratory analysis of metastatic site and number in the STAMPEDE \u201cM1\/RT\u201d comparison","author":"Ali","year":"2019"},{"key":"10.1016\/j.eururo.2019.08.006_bib0105","series-title":"Prostate cancer\u2014EAU guidelines","author":"EAU","year":"2018"},{"key":"10.1016\/j.eururo.2019.08.006_bib0110","series-title":"Prostate cancer. Version 2.2018. March 8","author":"National Comprehensive Cancer Network (NCCN)","year":"2018"},{"issue":"suppl_5","key":"10.1016\/j.eururo.2019.08.006_bib0115","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2019.08.006_bib0120","first-page":"1","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer ( STAMPEDE ): a randomised controlled phase 3 trial","volume":"6736","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2019.08.006_bib0125","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819306207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819306207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:06:09Z","timestamp":1759583169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819306207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0302283819306207"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.08.006","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abiraterone in \u201cHigh-\u201d and \u201cLow-risk\u201d Metastatic Hormone-sensitive Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}